Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 randomized double-blind placebo-controlled study of mitapivat in sickle cell disease
MOH_2022-01-12_010546Phase 3Recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mitapivat in sickle cell disease (SCD) (6 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Phase 2 anemia efficacy, Phase 2 safety and 2 more. Started Dec 2021; status: recruiting.
02
Drugs
mitapivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on MOH_2022-01-12_010546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-12_010546.